Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data suggests asciminib may help some leukemia patients

NCT ID NCT07644351

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within three months. The study is completed and provides real-world insight, but it was small and not a controlled trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
asciminib
What this could lead to
If results are positive, asciminib could offer a new treatment option for adults with Ph+ ALL who have run out of other choices.
What could go wrong
This is a small, retrospective chart review (37 patients), not a controlled trial. Results may not apply to all patients, and safety data is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

37 people

The number who actually took part.

Started

Dec 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Ph+ ALL who were enrolled in the asciminib MAP and received at least one dose of asciminib.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Adult patients enrolled in the asciminib MAP. * Diagnosis of Ph+ ALL. * Patients received at least one dose of asciminib through the asciminib MAP. * Appropriate approval obtained for the use of patient data including: * Signed informed consent form (ICF), or * ICF waiver granted by an Institutional review board/Independent Ethics Committee (IRB/IEC). Exclusion criteria • Age \< 18 years at the time of initiating asciminib treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia leukemia, acute lymphocytic, susceptibility to, 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphoblastic leukemia

Contacts and locations

Locations

  • Novartis Investigative Site

    Boston, Massachusetts, 02115, United States

  • Novartis Investigative Site

    Sydney, New South Wales, 2145, Australia

  • Novartis Investigative Site

    Montreal, H1T 2M4, Canada

  • Novartis Investigative Site

    Hong Kong, China

  • Novartis Investigative Site

    Le Chesnay, 78150, France

  • Novartis Investigative Site

    Ramat Gan, 52621, Israel

  • Novartis Investigative Site

    Ascoli Piceno, 63100, Italy

  • Novartis Investigative Site

    Bari, 70124, Italy

  • Novartis Investigative Site

    Catania, 95123, Italy

  • Novartis Investigative Site

    Cuneo, 12100, Italy

  • Novartis Investigative Site

    Pescara, 65124, Italy

  • Novartis Investigative Site

    Torino, 10126, Italy

  • Novartis Investigative Site

    Rotterdam, 3015, Netherlands

  • Novartis Investigative Site

    Islamabad, 44000, Pakistan

  • Novartis Investigative Site

    Rawalpindi, 46000, Pakistan

  • Novartis Investigative Site

    Bialystok, 15-276, Poland

  • Novartis Investigative Site

    Madrid, 28006, Spain

  • Novartis Investigative Site

    London, SE5 9RS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.